Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04630756 · ClinicalTrials.gov registry record · Phase 1
AZD4573 in Novel Combinations With Anti-cancer Agents in Patients With Advanced Blood Cancer
A Phase 1 study of Advanced Haematological Malignancies, sponsored by AstraZeneca.
- Completed
- Registry status
- Phase 1
- Development phase
- 40
- Enrollment target
- 17
- Study locations
NCT04630756 is a Phase 1 study of Advanced Haematological Malignancies that has completed, run by AstraZeneca. The registered enrollment target is 40 participants. The trial reports 17 study locations across 5 states.
The verdict
NCT04630756, a Phase 1 study of Advanced Haematological Malignancies, has completed, sponsored by AstraZeneca.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 40 participants
- Enrollment target
- 17
- Study locations
Study Summary
This is a modular, multicentre, open-label, non-randomised, Phase I/II, dose-setting and expansion study including an intra-participants dose ramp up. AZD4573 will be administered intravenously, in novel combinations with anti-cancer agents, to participants with relapsed/refractory (r/r) haematological malignancies.
Conditions Studied
Interventions
- DRUG Acalabrutinib
- DRUG AZD4573
Study Locations (17)
Other
- Research Site - Clayton
- Research Site - Nedlands
- Research Site - Lille
- Research Site - Dublin
- Research Site - Galway
- Research Site - Krakow
- Research Site - Seoul
- Research Site - Seoul
- Research Site - Seoul
- Research Site - Barcelona
- Research Site - Palma de Mallorca
- Research Site - Plymouth
California
- Research Site - Duarte
- Research Site - La Jolla
Texas
- Research Site - Houston
Utah
- Research Site - Salt Lake City
Quebec
- Research Site - Québec
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 40 participants |
| Start Date | 2021-02-17 |
| Est. Completion | 2025-02-27 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04630756
The ClinicalTrials.gov registry entry for NCT04630756 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 40 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is AstraZeneca, which has 1,285 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Advanced Haematological Malignancies appearing as the primary indexed condition, and to 2 interventions - of which Acalabrutinib is the first listed.
NCT04630756 reports 17 study locations spanning 5 distinct geographic areas - top geographies include Other, California, Texas.
Frequently Asked Questions
What is clinical trial NCT04630756 about?
NCT04630756 is a clinical study titled "AZD4573 in Novel Combinations With Anti-cancer Agents in Patients With Advanced Blood Cancer". This is a modular, multicentre, open-label, non-randomised, Phase I/II, dose-setting and expansion study including an intra-participants dose ramp up. AZD4573 will be administered intravenously, in novel combinations with anti-cancer agents, to participants with relapsed/refractory (r/r) haematologi...
What is the current status of trial NCT04630756?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 40 participants. The study started on 2021-02-17. Estimated completion is 2025-02-27.
What conditions does trial NCT04630756 study?
This clinical trial studies the following conditions: Advanced Haematological Malignancies.
What interventions are being tested in trial NCT04630756?
The interventions under investigation include: Acalabrutinib (DRUG), AZD4573 (DRUG).
Who is sponsoring clinical trial NCT04630756?
This trial is sponsored by AstraZeneca, which has 1,285 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04630756 being conducted?
This trial has 17 study locations across California, Texas, Utah, Quebec. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.